Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALA NASDAQ:DRRX NASDAQ:KIN NASDAQ:MRUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00-50.0%$0.00$0.00▼$0.01N/A-38,611 shs239 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRUSMerus$94.50+0.1%$77.04$33.19▼$95.04$7.15B1.261.26 million shs464,435 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%0.00%0.00%-90.00%DRRXDURECT0.00%0.00%0.00%+225.05%+34.51%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRUSMerus-0.21%-0.58%+36.44%+43.71%+77.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00-50.0%$0.00$0.00▼$0.01N/A-38,611 shs239 shsDRRXDURECT$1.91$1.91$0.48▼$2.64$59.31M0.92699,433 shsN/AKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shsMRUSMerus$94.50+0.1%$77.04$33.19▼$95.04$7.15B1.261.26 million shs464,435 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-50.00%0.00%0.00%-90.00%DRRXDURECT0.00%0.00%0.00%+225.05%+34.51%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%MRUSMerus-0.21%-0.58%+36.44%+43.71%+77.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/AKINKindred Biosciences 0.00N/AN/AN/AMRUSMerus 2.16Hold$93.12-1.46% DownsideCurrent Analyst Ratings BreakdownLatest DRRX, CALA, KIN, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025MRUSMerusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025MRUSMerusLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$95.00 ➝ $97.0010/5/2025MRUSMerusLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/30/2025MRUSMerusUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $97.009/30/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold9/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$112.00 ➝ $97.009/30/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$109.00 ➝ $97.009/30/2025MRUSMerusLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$97.009/29/2025MRUSMerusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$135.00 ➝ $97.007/29/2025DRRXDURECTNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/ADRRXDURECT$1.66M35.80N/AN/A$0.29 per share6.59KINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29MRUSMerus$36.13M197.80N/AN/A$9.46 per share9.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ADRRXDURECT-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%11/12/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/AMRUSMerus-$215.33M-$5.50N/AN/AN/A-685.64%-50.28%-42.00%10/30/2025 (Estimated)Latest DRRX, CALA, KIN, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025MRUSMerus-$1.20N/AN/AN/A$8.73 millionN/A8/12/2025Q2 2025DRRXDURECT-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million8/5/2025Q1 2025MRUSMerus-$1.17-$2.23-$1.06-$2.23$9.77 million$8.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ADRRXDURECTN/A0.980.95KINKindred Biosciences0.197.027.02MRUSMerusN/A8.398.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ADRRXDURECT28.03%KINKindred Biosciences66.89%MRUSMerus96.14%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%DRRXDURECT3.20%KINKindred Biosciences13.69%MRUSMerus3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableDRRXDURECT8031.05 million30.06 millionOptionableKINKindred Biosciences6345.46 millionN/AOptionableMRUSMerus3775.63 million72.84 millionOptionableDRRX, CALA, KIN, and MRUS HeadlinesRecent News About These CompaniesMerus (MRUS) Projected to Post Earnings on ThursdayOctober 23 at 4:49 AM | marketbeat.comShort Interest in Merus N.V. (NASDAQ:MRUS) Declines By 33.0%October 22 at 4:09 AM | marketbeat.comGenmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.October 21 at 8:12 AM | globenewswire.comTD Asset Management Inc Acquires 17,852 Shares of Merus N.V. $MRUSOctober 21 at 3:45 AM | marketbeat.comMerus (NASDAQ:MRUS) Hits New 1-Year High - What's Next?October 18, 2025 | marketbeat.comMerus N.V. $MRUS Shares Sold by Aberdeen Group plcOctober 17, 2025 | marketbeat.comMerus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ...October 14, 2025 | markets.businessinsider.comMerus announces initial interim data from phase 2 trial of petosemtamabOctober 14, 2025 | msn.comMerus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 14, 2025 | globenewswire.comMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular ...October 13, 2025 | markets.businessinsider.comMerus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in BostonOctober 13, 2025 | quiverquant.comQMerus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsOctober 13, 2025 | globenewswire.comMerus (MRUS): Assessing Valuation After Rapid Share Price GainsOctober 11, 2025 | finance.yahoo.comMerus (NASDAQ:MRUS) Hits New 12-Month High - Here's WhyOctober 10, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comMerus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold"October 7, 2025 | marketbeat.comLeerink Partners Downgrades Merus N.V. (MRUS)October 6, 2025 | msn.comMerus Sees Unusually Large Options Volume (NASDAQ:MRUS)October 2, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for Merus FY2027 Earnings?October 2, 2025 | marketbeat.comPlatinum Investment Management Ltd. Lowers Holdings in Merus N.V. $MRUSOctober 2, 2025 | marketbeat.comMerus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth PotentialOctober 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025Airlines Are Taking Off, With More Gains Left to Price InBy Gabriel Osorio-Mazilli | September 25, 2025Why Amazon’s Prime Day May Be the Catalyst for a Year-End RallyBy Sam Quirke | October 9, 2025Adobe Launches Premiere Pro on iPhone, Upside Ahead?By Gabriel Osorio-Mazilli | October 9, 2025AutoZone Pulls Into a Buy-the-Dip OpportunityBy Thomas Hughes | September 24, 2025DRRX, CALA, KIN, and MRUS Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0001 0.00 (-50.00%) As of 10/22/2025 09:30 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.DURECT NASDAQ:DRRXDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Merus NASDAQ:MRUS$94.50 +0.10 (+0.10%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
